273 related articles for article (PubMed ID: 30957179)
1. miR‑210‑3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3.
Jin Y; Wei J; Xu S; Guan F; Yin L; Zhu H
Mol Med Rep; 2019 Jun; 19(6):4946-4954. PubMed ID: 30957179
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1.
Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-449a inhibits proliferation and induces apoptosis by directly repressing E2F3 in gastric cancer.
Li X; Li H; Zhang R; Liu J; Liu J
Cell Physiol Biochem; 2015; 35(5):2033-42. PubMed ID: 25871967
[TBL] [Abstract][Full Text] [Related]
4. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
6. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-217 functions as a prognosis predictor and inhibits pancreatic cancer cell proliferation and invasion via targeting E2F3.
Yang J; Zhang HF; Qin CF
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4050-4057. PubMed ID: 29028097
[TBL] [Abstract][Full Text] [Related]
8. [Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells].
Guo P; Peng D; Xiong X; Zhang S
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1624-7. PubMed ID: 26607088
[TBL] [Abstract][Full Text] [Related]
9. [Effect of circBIRC6 targeting miR-367-3p on cisplatin resistance of ovarian cancer cells].
Zhang J; Bai HJ
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1062-1068. PubMed ID: 34695896
[No Abstract] [Full Text] [Related]
10. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
11. [Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP].
Zhang X; Li N; Wang YH; Huang Y; Xu NZ; Wu LY
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):174-7. PubMed ID: 19615253
[TBL] [Abstract][Full Text] [Related]
12. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
13. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
Chen Y; Wang L; Zhou J
J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
[TBL] [Abstract][Full Text] [Related]
14. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
15. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells.
Zhao WJ; Deng BY; Wang XM; Miao Y; Wang JN
Asian Pac J Cancer Prev; 2015; 16(6):2453-8. PubMed ID: 25824780
[TBL] [Abstract][Full Text] [Related]
16. Long non‑coding RNA HAND2‑AS1/miR‑106a/PTEN axis re‑sensitizes cisplatin‑resistant ovarian cells to cisplatin treatment.
Li L; Li L; Hu L; Li T; Xie D; Liu X
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34476500
[TBL] [Abstract][Full Text] [Related]
17. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells.
Zhou Y; Chen Q; Qin R; Zhang K; Li H
Tumour Biol; 2014 Dec; 35(12):12369-78. PubMed ID: 25179844
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy.
Yu JL; Gao X
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1688-1696. PubMed ID: 32141535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
